| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-11-03 | Curetis (Germany) | $110 Million (€100 million) | private placement | Baillie Gifford (UK) Chartwave Limited (UK) Coppel family (Mexico) Elma Investments (USA) Sigma Group (USA - NJ) | Cancer - Oncology - Immunological diseases - Infectious diseases | Private placement |
| 2015-11-02 | SEPCELL consortium [Tigenix (Belgium) CHU de Limoges (France) Cliniques Universitaires Saint-Luc (Belgium) Hospital Clínico San Carlos of the Servicio Madrileño de Salud in Madrid (Spain) Academic Medical Center of the University of Amsterdam (The Netherlands)] | €5.4 million | grant | European Commission’s Horizon 2020 programme | Infectious diseases | Grant |
| 2015-11-02 | Hercules Pharmaceuticals (The Netherlands) | € 3,5 million | grant | European Eurostars Programme (EU) | Cancer - Oncology | Grant |
| 2015-10-29 | InteRNA Technologies (The Netherlands) | $ 10.5 million | series A financing round | INKEF Capital (The Netherlands) Aglaia Oncology Fund II (The Netherlands) | Cancer - Oncology | Series A financing round |
| 2015-10-27 | Oryzon Genomics (Spain) | $19 million | private placement | Bank Solventis (UK) Catalan Institut of Finances (ICF) (Spain) Joseph Fernandez (USA) | Cancer - Oncology - Neurodegenerative diseases | Private placement |
| 2015-10-21 | Cortendo (Sweden)now Strongbridge Biopharma (Ireland) | $25 million | IPO | IPO | ||
| 2015-10-20 | Noxxon Pharma (Germany) | IPO | Cancer - Oncology | IPO | ||
| 2015-10-16 | Basilea Pharmaceutica (Switzerland) | IPO | Infectious diseases - Rare diseases | IPO | ||
| 2015-10-15 | AB Science (France) | € 50 million | loan | Crédit Agricole Corporate and Investment Bank (France) | Rare diseases - Cancer - Oncology | Establishment of a new subsidiary in the EU |
| 2015-10-15 | Keryx Pharmaceuticals (USA - MA) | $125 million | private placement | Private placement | ||
| 2015-10-14 | Minoryx Therapeutics (Spain) | €19.4 million ($21.7 million) | series A financing round | Ysios Capital (Spain) Kurma Partners (France) Roche Venture Fund (Switzerland) Idinvest Partners (France) Chiesi Ventures (Italy) Caixa Capital Risc (Spain) HealthEquity (Spain) | Rare diseases | Series A financing round |
| 2015-10-14 | Affimed (Germany) | $21.8 million (€ 19.2 million) | private placement | undisclosed existing shareholder | Cancer - Oncology | Private placement |
| 2015-10-13 | Audentes Therapeutics (USA - CA) | $65 million | series C financing round | Sofinnova Ventures (USA - CA) Redmile Group (USA - CA) RA Capital Management (USA - MA) funds and accounts advised by T. Rowe Price Associates (USA - MD), Rock Springs Capital Management (USA - MD) Cormorant Asset Management (USA - MA) Cowen Private Investments (USA - NY) Foresite Capital (USA - NY) OrbiMed (USA - NY) 5AM Ventures (USA - CA) Versant Ventures (USA - CA) Deerfield Management Company (USA - NY) Venrock (USA - CA) | Rare diseases - Genetic diseases | Series C financing round |
| 2015-10-13 | Prima Biomed (Australia) | €1 million | private placement | Nyenburgh Investment Partners (NYIP) (The Netherlands) | Cancer - Oncology | Private placement |
| 2015-10-12 | Medgenics (USA - Israel) | $46 million | private placement | Rare diseases | Private placement | |
| 2015-10-12 | Gamida Cell (Israel) | $15 million | private placement | Novartis (Switzerland) | Private placement | |
| 2015-10-12 | Sucampo Pharmaceuticals (USA - MA) | $250 million | loan | Gastrointestinal diseases Immunological diseases Ophtalmological diseases Cancer - Oncology | Loan | |
| 2015-10-09 | Sarepta Therapeutics (USA - MA) | $127 Million | IPO | Rare diseases - Genetic diseases - Neuromuscular diseases | IPO | |
| 2015-10-02 | Galapagos (Belgium) | €1.2 million | capital increase | Capital increase | ||
| 2015-10-01 | Immune Pharmaceuticals (USA - MA, Israel) | $21.5 million | loan | Discover Growth Fund (Cayman Islands) Hercules Technology Growth Capital (USA - CA) | Loan |
